Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 8/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701615 | 0.90 | GPR119 (0.52) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL10246190 | 0.87 | NAMPT (0.49) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL3322074 | 0.86 | TACR1 (0.47) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL701369 | 0.86 | NAMPT (0.48) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL703396 | 0.86 | CCR5 (0.49) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL557992 | 0.86 | TACR1 (0.60) | GPR119OPRD1OPRK1TACR1CCR5 | |
| SCHEMBL10246201 | 0.85 | GPR119 (0.50) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL10246265 | 0.85 | NAMPT (0.48) | GPR119NAMPTOPRD1OPRK1TACR1 | |
| SCHEMBL30017524 | 0.85 | GPR119 (0.54) | GPR119NAMPTOPRD1OPRK1JAK2 | |
| SCHEMBL26633633 | 0.85 | GPR119 (0.54) | GPR119NAMPTOPRD1OPRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2022-08-02 | — | — | US | disclosed |
| US-20200369643-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-11-26 | — | — | US | disclosed |
| US-20200369643-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-11-26 | — | — | US | disclosed |
| US-10774065-B2 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2020-09-15 | — | — | US | disclosed |
| US-10774065-B2 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2020-09-15 | — | — | US | disclosed |
| US-10301278-B2 | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10301278-B2 | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180362496-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| US-10093646-B2 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| WO-2015107493-A1 | 1 -PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| EP-2132203-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301278-B2 | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | PTPN1, PTPN5, PTPN7 | GPR119 739/4885NAMPT 3682/4885OPRD1 4004/4885 |
| US-10774065-B2 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
| US-10093646-B2 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
| US-20180362496-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | TTBK1, ERBB2, TEC | GPR119 808/4885NAMPT 983/4885OPRD1 4819/4885 |
| US-20200369643-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | GPR119 454/4885NAMPT 3909/4885OPRD1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.